All In Biotech

Drug Trial Radar · NCT01762046

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,033

Actual

Start

Jan 2008

Primary completion

Dec 2015

Study completion Dec 2025

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Brigham and Women's Hospital; Joslin Diabetes Center; Broad Institute of MIT and Harvard
First posted
Jan 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • GlipizideDrug

  • MetforminDrug

  • Oral Glucose Tolerance TestOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to GenotypeTime frame: 0, 30, 60, 90, 120, 180 and 240 minutes post 5mg oral glipizide dose, Day 1 (visit 1)
  2. Glipizide Response as Measured by Area Under the Insulin Curve Between Time 0 and 240 Minutes According to GenotypeTime frame: 0,30,60,90,120,180 and 240 minutes on Day 1 (Visit 1)
  3. Metformin Response - Change in Fasting Glucose From Visit 1 to Visit 2Time frame: Day 1 (Visit 1) and Day 8 (Visit 2)
  4. Metformin Response - Change in HOMA-IR From Visit 1 to Visit 2Time frame: Day 1 (Visit 1) and Day 8 (Visit 2)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Joslin Diabetes Center

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.